Data capture company, uMotif, has raised £2.4 million in its latest funding round, which was led by Albion Capital — an independent investment manager — along with several angel investors.
Funding
The funds from this latest investment round will be used to scale up the company’s team and build on the capabilities of its software platform — which provides patient-facing technology required to capture real-world data for clinical research initiatives —such as new language integration. The technology is already in use by top pharma companies across Europe and North America, including AstraZeneca, Novartis and UCB across multiple therapeutic areas.
“uMotif has developed a game-changing product for the health and pharma industries, opening new doors to creating more successful treatments, enabled through unprecedented patient engagement. Since launching five years ago, Bruce and Ben have done a fantastic job in positioning uMotif as one of the world leaders in a field which is notoriously hard to penetrate with new technology,” said Andrew Elder, partner at Albion Capital. “We are hugely excited about the growth potential of the company moving forward and, as the first institutional investor to come aboard, we look forward to working with the team to fulfil their expansion strategy.”
Bruce Hellman, CEO, uMotif, added: “We’re delighted to secure this round of funding. We see this investment as adding rocket fuel to fire that’s already burning brightly. It will enable us to bring on even more world class talent and remain at the forefront of patient-centric technology.”